Long term prognosis of heart failure after acute coronary syndromes without ST elevation

Postgraduate Medical Journal

Volumn 82, Issue 963, 2006, Pages 55-59

  Shibata, M C ^b,c   Collinson, J ^b   Taneja, A K ^b   Bakhai, A ^d   Flather, M D ^a,e  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c UNIVERSITY OF ALBERTA   (Canada)

^d ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; NITRATE; POTASSIUM CHANNEL STIMULATING AGENT;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; REGISTER; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNITED KINGDOM; UNSTABLE ANGINA PECTORIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COHORT STUDIES; CORONARY ARTERY BYPASS; FEMALE; GREAT BRITAIN; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MYOCARDIAL INFARCTION; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; SURVIVAL ANALYSIS;

EID: 30944466281     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2005.035766     Document Type: Article

References (22)

1. McGuire AJ, Stewart S, Jenkins A, et al. The current cost of heart failure to the National Health Service in the UK. European Journal of Heart Failure 2002;4:361-71.
2. Kannel WB. Heart failure. In: Poole-Wilson PA, Colucci WS, Massie BM, et al, eds. New York: Churchill Livingstone, 1997:279-88.
3. Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham heart study subjects. Circulation 1993;88:107-15.
4. Cowie MR, Wood DA, Thompson SG, et al. Incidence and aetiology of heart failure. A population-based study. Eur Heart J 1999;20:421-8.
5. Collinson J, Flather MD, Fox KA, et al. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK). Eur Heart J 2000;21:1450-7.
6. CIBIS-II Investigators and Committees. The cardiac insufficiency and bisoprolol study II (CIBIS-II): a randomized trial. Lancet 1999;353:9-13.
7. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention rrial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-7.
8. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-9.
9. Steg PG, Dabbous OH, Feldman OJ, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes. Observations from the Global Registry or Acute Coronary Events (GRACE). Circulation 2004;109:494-9.
10. Marchioli R, Avanzini F, Barzi F, et al. Assessment of absolute risk of death after myocardial infarction by use of multiple risk-factors assessment equations: GISSI-Prevenzione mortality risk chart. Eur Heart J 2001;22:2085-103.
11. Reference withdrawn.
12. Newby LK, Bapkhar MV, White H, et al. Predictors of 90 day outcome in stabilized patients after acute coronary syndromes. Eur Heart J 2003;2:172-81.
13. Richards AM, Nichols MG, Troughton RW, et al. Antecendent hypertension and heart failure after myocardiol infarction. J Am Coll Cardiol 2002;39:1182-8.
14. de Kam PJ, Nicolosi GL, Voors AA, et al. Prediction of 6 months left ventricular dilatation after myocardial infarction in relation to cardiac morbidity and mortality. Application of a new dilatation model to GISSI 3 data. Eur Heart J 2002;3:536-42.
15. Zornoff LA, Skali H, Pfeffer MA, et al. Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. J Am Coll Cardiol 2002;39:1450-5.
16. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acuter coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT investigators. Circulation 2000;101:2557-67.
17. Herlitz J, Karlson BW, Lindqvist J, et al. Prognosis and risk indicators of death during a period of 10 years for women admitted to the emergency department with a suspected acute coronary syndrome. Int J Cardiol 2002;82:259-68.
18. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
19. EURopean trial On reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
20. Argenziano M, Spitritz HM, Whay W, et al. Risk stratification for coronary bypass surgery in patients with left ventricular dysfunction. Analysis of the CABG patch trial database. Circulation 1999;100:11119-24.
21. Alderman EL, Bourassa MG, Cohen LS, et al. Ten-year follow-up of survival and myocardial infarction in the randomized Coronary artery surgery study. Circulation 1990;82:1629-46.
22. Cleland JG, Freemantle N, Ball SG, et al. The heart failure revascularisation trial (HEART): rationale, design and methodology. European Journal of Heart Failure 2003;5:295-303.